Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. has filed an 8-K describing a petition to the Delaware Court of Chancery under Section 205 of the Delaware General Corporation Law. The company asks the court to validate a charter amendment that increased authorized common shares from 295,000,000 to 390,000,000 and to confirm the validity of shares issued based on that change.
The petition follows a stockholder lawsuit challenging whether special Series C preferred stock could vote on the 2024 share increase proposal. Ocugen states it acted in good faith, that a correction filing fixed any drafting issue, and that about 33,009,874 shares have been issued in reliance on the amendment. A hearing on the petition is scheduled for May 6, 2026, and the stockholder plaintiff does not oppose the requested relief.
Ocugen, Inc. reported fourth quarter and full year 2025 results and a broad business update focused on its gene therapy pipeline. For 2025, total revenue was $4,413 thousand while operating expenses reached $67,329 thousand, leading to a net loss of $67,846 thousand, wider than 2024. Cash, cash equivalents and restricted cash fell to roughly the high teens in millions of dollars, and total stockholders’ equity turned negative.
Clinically, enrollment is complete in the 140-patient Phase 3 liMeliGhT trial of OCU400 for retinitis pigmentosa, with topline data planned in the first quarter of 2027 to support a Biologics License Application. OCU410 for geographic atrophy showed preliminary Phase 2 results including a 46% reduction in lesion growth versus control at 12 months and a 60% slower rate of ellipsoid zone loss in treated eyes. Management is targeting three BLA submissions for OCU400, OCU410ST and OCU410 between 2026 and 2028. To bolster liquidity, Ocugen completed a $22.5 million underwritten registered direct offering in January 2026 and notes it may receive up to an additional $30 million if previously issued warrants are exercised, which together underpin guidance for a cash runway into at least the fourth quarter of 2026.
Ocugen, Inc. appointed Rita Johnson-Greene as Chief Financial Officer effective February 9, 2026, with her role as principal financial officer beginning after the filing of the Annual Report for the year ended December 31, 2025. Current principal financial officer Ramesh Ramachandran will continue as Chief Accounting Officer and principal accounting officer.
Under her employment agreement, Ms. Johnson-Greene will receive a $440,000 annual base salary, an initial target bonus opportunity of up to 45% of base salary, and a $90,000 sign-on bonus subject to repayment if she departs within one year. She was granted options to purchase 750,000 shares of common stock and 500,000 restricted stock units that vest in equal annual installments over three years. The agreement includes 12 months of salary continuation and COBRA premium support upon certain terminations, with additional bonus and full equity vesting acceleration if such a termination occurs around a change in control.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Ocugen Inc. common stock. Vanguard reports beneficial ownership of 16,475,562 shares, representing 5.27% of the class as of 12/31/2025.
Vanguard has shared voting power over 1,981,345 shares and shared dispositive power over 16,475,562 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of influencing control of Ocugen.
Ocugen, Inc. completed its previously announced underwritten offering of 15,000,000 shares of common stock at $1.50 per share. The company states that the proceeds from this stock sale are expected to extend its cash runway into the fourth quarter of 2026, giving it more time to fund operations and development plans without needing additional financing in the near term. The transaction and related details were also highlighted in a press release filed as an exhibit.
Ocugen, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc. to sell 15,000,000 shares of common stock at $1.50 per share in an underwritten public offering. The offering is expected to close on or about January 22, 2026, subject to customary closing conditions.
Ocugen expects to receive approximately $20.8 million in net proceeds after underwriting discounts, commissions and estimated expenses. The company plans to use the cash for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The shares are being issued under an effective Form S-3 shelf registration and a January 20, 2026 prospectus supplement.
Ocugen, Inc. is offering 15,000,000 shares of common stock at $1.50 per share, for gross proceeds of $22.5 million and estimated net proceeds of about $20.85 million. The company expects to use the cash for general corporate purposes, including working capital, capital expenditures, and administrative costs, and may also invest in complementary businesses or technologies.
Shares outstanding will rise from 312,319,623 as of September 30, 2025 to 327,888,374, creating immediate dilution of $1.43 per share for new investors based on an as adjusted net tangible book value of $0.07. Ocugen highlights ongoing losses, substantial doubt about its ability to continue as a going concern without additional funding, and the likelihood of further capital raises. The filing also describes late-stage gene therapy programs, including OCU410 and OCU400, with recent positive clinical data in retinal diseases.
Ocugen, Inc. filed a report describing new clinical progress for its eye disease pipeline. The company announced positive preliminary 12‑month data from both its Phase 1 and Phase 2 ArMaDa trials of OCU410 (AAV5‑RORA), a modifier gene therapy candidate being studied for geographic atrophy caused by dry age‑related macular degeneration, a severe form of vision loss.
Ocugen also furnished a press release and an investor presentation as exhibits, which elaborate on the OCU410 results and program. The company cautions that these findings are preliminary and that clinical trial data, including from OCU400 and OCU410ST, may differ as studies progress and as regulators review results. It highlights the possibility that new or reanalyzed data could be interpreted differently and refers readers to its prior annual and other reports for a fuller discussion of risks.
Ocugen, Inc. reported new equity awards to its Chief Executive Officer and director, Shankar Musunuri. On January 2, 2026, he received 3,123,201 performance stock units, each representing a contingent right to one share of common stock upon achievement of performance goals and continued service. On the same date, he was also granted an option to buy 3,123,201 shares of common stock at an exercise price of $1.38 per share, vesting annually in equal installments over three years starting January 2, 2027, subject to continued service.
Following these transactions, Musunuri beneficially owned 4,955,924 shares of Ocugen common stock directly and 1,145,299 shares indirectly through KVM Holdings, LLC, where he has voting and investment power over the shares held.
Ocugen, Inc. reported that its Board of Directors approved a special equity grant for its Chief Executive Officer, Dr. Shankar Musunuri. On December 12, 2025, following a review of his total equity ownership versus founder CEOs in the company’s peer group, the Board authorized an additional award of 9,369,604 Performance Restricted Stock Units (PSUs), to be granted on January 2, 2026, on top of his regular annual equity award.
The PSUs carry a three-year performance period ending December 31, 2028. Vesting depends on the Compensation Committee determining that specific milestones have been achieved: two-thirds of the PSUs are tied to certain regulatory milestones, and one-third depends on a stock performance-related milestone during the performance period. The units will be settled in common stock once the Compensation Committee certifies milestone achievement, and only if Dr. Musunuri continues serving with Ocugen through the applicable achievement date; any unearned or unvested PSUs at the end of the period, or upon termination, will be forfeited.